JOUNCE THERPEUTC CM

Jounce Therapeutics Reports Third Quarter 2019 Financial Results

07 十一月 2019 11:30:00 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

05 十一月 2019 13:05:00 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019

31 十月 2019 12:00:42 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

01 十月 2019 23:01:01 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

17 九月 2019 13:02:15 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

28 八月 2019 13:00:41 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Reports Second Quarter 2019 Financial Results

07 八月 2019 11:30:21 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019

31 七月 2019 13:01:53 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation

23 七月 2019 21:00:11 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer

18 六月 2019 13:00:37 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Upcoming Investor Conferences in June

11 六月 2019 13:00:30 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Reports First Quarter 2019 Financial Results

08 五月 2019 11:31:01 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019

01 五月 2019 13:00:10 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting

03 四月 2019 13:02:00 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting

02 四月 2019 18:02:00 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

06 三月 2019 11:30:10 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

04 三月 2019 13:01:57 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019

28 二月 2019 13:00:13 条件 Nasdaq GlobeNewswire

Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting

27 二月 2019 21:35:24 条件 Nasdaq GlobeNewswire

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

03 一月 2019 13:00:46 条件 Nasdaq GlobeNewswire